查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030年bupivacaine hydrochloride注射液全球市场预测：依浓度、容量、包装、应用、最终用户及地区分析
市场调查报告书
商品编码
1383322

2030年bupivacaine hydrochloride注射液全球市场预测：依浓度、容量、包装、应用、最终用户及地区分析

Bupivacaine Hydrochloride Injection Market Forecasts to 2030 - Global Analysis By Concentration, Volume (Small Volume, Medium Volume and Large Volume ), Packaging, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球bupivacaine hydrochloride注射液市场规模为11.2021亿美元，预计到2030年将达到18.7027亿美元，预测期内年复合成长率为7.6%。

bupivacaine hydrochloride注射液是一种用于麻醉和疼痛管理领域的药物。透过给药给予局部麻醉剂，使身体的某些部位麻木。布比卡因的作用是阻断疼痛讯号沿着神经纤维的传递。布比卡因应谨慎给药，尤其是高风险病患或需要密切监测的情况下。布比卡因不应用于已知对该药物过敏的患者。

根据美国整形外科学会 (AAOS) 的研究，美国每年进行超过 432,000 例脊椎融合手术。根据医疗保健研究与品质机构的一项研究，美国年度进行超过 79 万美国膝关节关节重建手术。

对门诊手术中心的需求不断增长

ASC 越来越多地执行各种外科手术，包括整形外科、眼科、妇科和牙科。这些中心喜欢使用局部麻醉剂，例如bupivacaine hydrochloride注射液，因为它们提供有效的麻醉，同时让患者快速康復并在当天回家。 ASC 也以其经济高效的医疗保健服务方式而闻名。阿片类药物使用的最小化、副作用风险的降低以及快速治疗也正在推动市场成长。

严格的法规核准流程

美国FDA 等法规机构为药品的安全性和有效性制定了高标准。即使在监管核准流程上投入了大量资金，也存在核准被拒绝或延迟的风险。即使在核准后，公司也必须遵守持续的上市后监督和报告要求。因此，法规核准情况可能会影响定价和报销决策。满足这些标准至关重要，但对市场来说可能是一个挑战。

扩大手术程序

无论大小，外科手术通常都需要麻醉，以确保患者在手术过程中的舒适和安全。bupivacaine hydrochloride是一种广泛使用的局部麻醉剂，可在手术期间和手术后提供有效的镇痛作用。bupivacaine hydrochloride常用于局部麻醉技术。微创手术的增加通常涉及局部麻醉技术。广泛的外科专业和微创手术的应用正在推动市场成长。

与仿製药的竞争

bupivacaine hydrochloride布比卡因注射液的仿製药通常以比品牌产品更低的价格进入市场。这可能会导致价格竞争并降低先发製造商的报酬率。有时这会导致製造商之间合併、收购和联盟，以实现规模经济并保持盈利。它还可能导致市场饱和。所有这些因素都阻碍了市场需求。

COVID-19 的影响

COVID-19大流行对製药业产生了多种影响。由于工厂关闭、运输限制和劳动力短缺，疫情导致全球供应链中断。这影响了bupivacaine hydrochloride注射液的可用性和分销。在疫情高峰期，许多择期手术被推迟或取消，以节省资源并降低感染风险。这场大流行也引起了人们对医疗保健中有效疼痛管理的重要性的关注。这可能会对医疗保健利用模式产生长期影响，并影响对bupivacaine hydrochloride注射液等产品的需求。

慢性疼痛管理领域预计将成为预测期内最大的领域

慢性疼痛管理领域预计将出现良好的成长。bupivacaine hydrochloride常用于硬脊膜外麻醉和神经阻断等局部麻醉。它可以缓解身体特定部位的疼痛，而不会导致意识丧失。与其他局部麻醉剂相比，bupivacaine hydrochloride的全身吸收率较低。它们更长的作用时间、维持肌肉力量以及提高患者舒适度和满意度正在推动这一领域的需求。

预计专科诊所和疼痛管理中心领域在预测期内的年复合成长率最高

预计专科诊所和疼痛管理中心部门在预测期内将出现最高的年复合成长率。bupivacaine hydrochloride注射是疼痛管理中心的宝贵武器，为缓解疼痛、增加患者舒适度和帮助復原提供了可靠有效的方法。布比卡因比其他局部麻醉剂的作用持续时间更长。由于其作用时间长，布比卡因在门诊和手术后需要长时间缓解疼痛的门诊病人中特别有用。

比最大的地区

预计亚太地区在预测期内将占据最大的市场占有率。由于人口成长、医疗保健机会的改善和高龄化因素，亚太地区的外科手术数量不断增加。中国、印度、日本、韩国和澳洲正在大力投资卫生基础设施。随着先进医疗技术和医疗设备的引进，该地区的外科治疗品质不断提高。此外，对疼痛管理的认识不断提高以及强大的主要企业的存在正在推动市场需求。

复合年复合成长率最高的地区：

预计北美在预测期内的年复合成长率最高。该地区以其医疗保健技术进步而闻名。随着北美高龄化老化，慢性疼痛呈现上升趋势。北美的外科手术比例也很高，包括选择性和非选择性手术。此外，该地区的药品市场竞争非常激烈，既有非专利药製造商，也有品牌製造商。此外，研发配合措施和激烈的市场竞争正在推动北美市场的发展。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球bupivacaine hydrochloride注射液市场：依浓度分类

  • 介绍
  • 0.25%
  • 0.50%
  • 0.75%
  • 其他浓度

第6章全球bupivacaine hydrochloride注射液市场：依数量

  • 介绍
  • 小容量（5ML）
  • 中容量（10ML）
  • 大容量（20ML以上）

第7章全球bupivacaine hydrochloride注射液市场：依包装分类

  • 介绍
  • 单给药小瓶
  • 多剂量小瓶
  • 安瓿

第8章全球bupivacaine hydrochloride注射液市场：依应用分类

  • 介绍
  • 手术麻醉
  • 产科麻醉
  • 慢性疼痛管理
  • 整形外科手术
  • 心血管手术
  • 神经治疗
  • 牙科手术
  • 其他用途

第9章全球bupivacaine hydrochloride注射液市场：依最终用户分类

  • 介绍
  • 日间手术中心 (ASC)
  • 医院和诊所
  • 专科诊所和疼痛管理中心
  • 牙医诊所
  • 其他最终用户

第10章全球bupivacaine hydrochloride注射液市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Hikma Pharmaceuticals
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Baxter International Inc.
  • AstraZeneca
  • AuroMedics Pharma LLC
  • Areva
  • SteriMax Inc.
  • Shanghai Harvest Pharmaceutical Co.
  • Southwest Pharma
  • Hunan Kelun Pharmaceutical
  • Aurobindo pharma
  • Sagent Pharmaceuticals
Product Code: SMRC24172

According to Stratistics MRC, the Global Bupivacaine Hydrochloride Injection Market is accounted for $1120.21 million in 2023 and is expected to reach $1870.27 million by 2030 growing at a CAGR of 7.6% during the forecast period. Bupivacaine Hydrochloride Injection is a medication used in the field of anaesthesia and pain management. It is a local anaesthetic that is administered via injection to numb specific areas of the body. Bupivacaine works by blocking the transmission of pain signals along nerve fibers. Bupivacaine should be administered with caution, especially in high-risk patients or in situations where close monitoring is required. Bupivacaine should not be used in patients with known allergies to the drug.

According to the American Academy of Orthopedic Surgeons (AAOS) survey, over 432,000 spinal fusions are performed in the United States every year. As per the Agency for Healthcare Research and Quality, more than 790,000 knee replacements are performed yearly in the United States.

Market Dynamics:

Driver:

Rising demand for ambulatory surgical centers

ASCs are increasingly performing a wide range of surgical procedures, including orthopedic, ophthalmic, gynaecological, and dental surgeries. These centers often prefer using local anaesthetics like Bupivacaine Hydrochloride Injection for their ability to provide effective anaesthesia while allowing patients to recover quickly and go home on the same day. Also, ASCs are known for their cost-effective approach to healthcare delivery. As well as, its minimization of opioid usage, reduced risk of side effects and quick turnaround times are fuelling the market growth.

Restraint:

Stringent regulatory approval process

Regulatory authorities, such as the FDA in the United States, set high safety and efficacy standards for medications. Even after significant investment in the regulatory approval process, there is a risk of rejection or delays in approval. Even after approval, companies must comply with ongoing post-market surveillance and reporting requirements. Therefore, regulatory approval status can influence pricing and reimbursement decisions. Meeting these standards is essential but can be challenging for the market.

Opportunity:

Growing surgical procedures

Surgical procedures, whether major or minor, typically require anaesthesia to ensure patient comfort and safety during the operation. Bupivacaine Hydrochloride is a widely used local anaesthetic that provides effective pain relief during and after surgery. Bupivacaine Hydrochloride is commonly used in regional anaesthesia techniques. The rise in minimally invasive surgical procedures often involves regional anaesthesia techniques. Its applications in wide range of surgical specialties and minimally invasive procedures are propelling the market growth.

Threat:

Competition from generic versions

Generic versions of bupivacaine hydrochloride injections typically enter the market at lower prices than their branded counterparts. This can lead to price competition and erosion of profit margins for the original manufacturer. This may prompt mergers, acquisitions, or partnerships among manufacturers to achieve economies of scale and maintain profitability. It can also lead to market saturation. All these elements hinder the market demand.

COVID-19 Impact

The COVID-19 pandemic had several impacts on the pharmaceutical industry. The pandemic led to disruptions in global supply chains due to lockdowns, restrictions on transportation, and workforce shortages. This affected the availability and distribution of Bupivacaine Hydrochloride Injection. Many elective surgeries were postponed or cancelled during the peak of the pandemic to conserve resources and reduce the risk of transmission. Also, the pandemic brought attention to the importance of effective pain management in healthcare. So, there may be longer-term effects on healthcare utilization patterns, which could influence the demand for products like Bupivacaine Hydrochloride Injection.

The chronic pain management segment is expected to be the largest during the forecast period

The chronic pain management segment is estimated to have a lucrative growth. Bupivacaine Hydrochloride is often used in regional anaesthesia techniques such as epidural and nerve block procedures. It provides pain relief in specific areas of the body without causing a loss of consciousness. Compared to some other local anaesthetics, bupivacaine hydrochloride has a lower rate of systemic absorption. Its longer duration of action, preservation of muscle strength, enhanced patient comfort and satisfaction drives the segment demand.

The specialty clinics & pain management centers segment is expected to have the highest CAGR during the forecast period

The specialty clinics & pain management centers segment is anticipated to witness the highest CAGR growth during the forecast period. Bupivacaine Hydrochloride Injection is a valuable tool in the arsenal of pain management centers, offering a reliable and effective means to alleviate pain, enhance patient comfort, and support rehabilitation efforts. Bupivacaine has a longer duration of action compared to some other local anaesthetics. Due to its prolonged duration of action, bupivacaine can be especially useful in ambulatory or outpatient settings where extended pain relief is needed after a procedure.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. The Asia-Pacific region has witnessed a rise in surgical procedures, driven by factors such as population growth, increased access to healthcare, and a rising aging population. China, India, Japan, South Korea, and Australia, have been investing significantly in their healthcare infrastructure. The adoption of advanced medical technologies and equipment has improved the quality of surgical care in the region. Further, the rising awareness of pain management and presence of strong key players are fuelling the market demand.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The region is well known for its technological advancements in healthcare. The aging population in North America has led to an increase in chronic pain conditions. Also, North America has a high rate of surgical procedures, including both elective and non-elective surgeries. In addition, the market for pharmaceuticals in the region is highly competitive, with both generic and brand-name manufacturers. Further, its research and development initiatives and strong market competition is boosting the North American market.

Key players in the market

Some of the key players profiled in the Bupivacaine Hydrochloride Injection Market include: Hikma Pharmaceuticals, Pfizer Inc., Fresenius Kabi AG, Baxter International Inc., AstraZeneca, AuroMedics Pharma LLC, Areva, SteriMax Inc., Shanghai Harvest Pharmaceutical Co., Southwest Pharma, Hunan Kelun Pharmaceutical, Aurobindo pharma and Sagent Pharmaceuticals.

Key Developments:

In December 2021, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced that it launched Bupivacaine HCl Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc.

In July 2016, India-based pharmaceutical manufacturing company, Aurobindo pharma has got approval from the US food and drug administration (USFDA) to produce and market its anaesthetic Bupivacaine Hydrochloride injection in the American market.

Concentrations Covered:

  • 0.25%
  • 0.50%
  • 0.75%
  • Other Concentrations

Volumes Covered:

  • Small Volume (5 ML)
  • Medium Volume (10 ML)
  • Large Volume (>20 ML)

Packagings Covered:

  • Single-Dose Vials
  • Multi-Dose Vials
  • Ampoules

Applications Covered:

  • Surgical Anaesthesia
  • Obstetric Anaesthesia
  • Chronic Pain Management
  • Orthopedic Procedures
  • Cardiovascular Procedures
  • Neurological Procedures
  • Dental Procedures
  • Other Applications

End Users Covered:

  • Ambulatory Surgical Centers (ASCs)
  • Hospitals & Clinics
  • Specialty Clinics & Pain Management Centers
  • Dental Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bupivacaine Hydrochloride Injection Market, By Concentration

  • 5.1 Introduction
  • 5.2 0.25%
  • 5.3 0.50%
  • 5.4 0.75%
  • 5.5 Other Concentrations

6 Global Bupivacaine Hydrochloride Injection Market, By Volume

  • 6.1 Introduction
  • 6.2 Small Volume (5 ML)
  • 6.3 Medium Volume (10 ML)
  • 6.4 Large Volume (>20 ML)

7 Global Bupivacaine Hydrochloride Injection Market, By Packaging

  • 7.1 Introduction
  • 7.2 Single-Dose Vials
  • 7.3 Multi-Dose Vials
  • 7.4 Ampoules

8 Global Bupivacaine Hydrochloride Injection Market, By Application

  • 8.1 Introduction
  • 8.2 Surgical Anesthesia
  • 8.3 Obstetric Anesthesia
  • 8.4 Chronic Pain Management
  • 8.5 Orthopedic Procedures
  • 8.6 Cardiovascular Procedures
  • 8.7 Neurological Procedures
  • 8.8 Dental Procedures
  • 8.9 Other Applications

9 Global Bupivacaine Hydrochloride Injection Market, By End User

  • 9.1 Introduction
  • 9.2 Ambulatory Surgical Centers (ASCs)
  • 9.3 Hospitals & Clinics
  • 9.4 Specialty Clinics & Pain Management Centers
  • 9.5 Dental Clinics
  • 9.6 Other End Users

10 Global Bupivacaine Hydrochloride Injection Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Hikma Pharmaceuticals
  • 12.2 Pfizer Inc.
  • 12.3 Fresenius Kabi AG
  • 12.4 Baxter International Inc.
  • 12.5 AstraZeneca
  • 12.6 AuroMedics Pharma LLC
  • 12.7 Areva
  • 12.8 SteriMax Inc.
  • 12.9 Shanghai Harvest Pharmaceutical Co.
  • 12.10 Southwest Pharma
  • 12.11 Hunan Kelun Pharmaceutical
  • 12.12 Aurobindo pharma
  • 12.13 Sagent Pharmaceuticals

List of Tables

  • Table 1 Global Bupivacaine Hydrochloride Injection Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bupivacaine Hydrochloride Injection Market Outlook, Concentration (2021-2030) ($MN)
  • Table 3 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.25% (2021-2030) ($MN)
  • Table 4 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.50% (2021-2030) ($MN)
  • Table 5 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.75% (2021-2030) ($MN)
  • Table 6 Global Bupivacaine Hydrochloride Injection Market Outlook, Other Concentrations (2021-2030) ($MN)
  • Table 7 Global Bupivacaine Hydrochloride Injection Market Outlook, Volume (2021-2030) ($MN)
  • Table 8 Global Bupivacaine Hydrochloride Injection Market Outlook, Small Volume (5 ML) (2021-2030) ($MN)
  • Table 9 Global Bupivacaine Hydrochloride Injection Market Outlook, Medium Volume (10 ML) (2021-2030) ($MN)
  • Table 10 Global Bupivacaine Hydrochloride Injection Market Outlook, Large Volume (>20 ML) (2021-2030) ($MN)
  • Table 11 Global Bupivacaine Hydrochloride Injection Market Outlook, Packaging (2021-2030) ($MN)
  • Table 12 Global Bupivacaine Hydrochloride Injection Market Outlook, Single-Dose Vials (2021-2030) ($MN)
  • Table 13 Global Bupivacaine Hydrochloride Injection Market Outlook, Multi-Dose Vials (2021-2030) ($MN)
  • Table 14 Global Bupivacaine Hydrochloride Injection Market Outlook, Ampoules (2021-2030) ($MN)
  • Table 15 Global Bupivacaine Hydrochloride Injection Market Outlook, Application (2021-2030) ($MN)
  • Table 16 Global Bupivacaine Hydrochloride Injection Market Outlook, Surgical Anesthesia (2021-2030) ($MN)
  • Table 17 Global Bupivacaine Hydrochloride Injection Market Outlook, Obstetric Anesthesia (2021-2030) ($MN)
  • Table 18 Global Bupivacaine Hydrochloride Injection Market Outlook, Chronic Pain Management (2021-2030) ($MN)
  • Table 19 Global Bupivacaine Hydrochloride Injection Market Outlook, Orthopedic Procedures (2021-2030) ($MN)
  • Table 20 Global Bupivacaine Hydrochloride Injection Market Outlook, Cardiovascular Procedures (2021-2030) ($MN)
  • Table 21 Global Bupivacaine Hydrochloride Injection Market Outlook, Neurological Procedures (2021-2030) ($MN)
  • Table 22 Global Bupivacaine Hydrochloride Injection Market Outlook, Dental Procedures (2021-2030) ($MN)
  • Table 23 Global Bupivacaine Hydrochloride Injection Market Outlook, Other Applications (2021-2030) ($MN)
  • Table 24 Global Bupivacaine Hydrochloride Injection Market Outlook, End User (2021-2030) ($MN)
  • Table 25 Global Bupivacaine Hydrochloride Injection Market Outlook, Ambulatory Surgical Centers (ASCs) (2021-2030) ($MN)
  • Table 26 Global Bupivacaine Hydrochloride Injection Market Outlook, Hospitals & Clinics (2021-2030) ($MN)
  • Table 27 Global Bupivacaine Hydrochloride Injection Market Outlook, Specialty Clinics & Pain Management Centers (2021-2030) ($MN)
  • Table 28 Global Bupivacaine Hydrochloride Injection Market Outlook, Dental Clinics (2021-2030) ($MN)
  • Table 29 Global Bupivacaine Hydrochloride Injection Market Outlook, Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.